David Whitlock of AOBiome | Q&A

Chemical engineer David Whitlock has made a splash in the media as of late, due to his lack of “splash”—as in the man hasn’t bathed in 12 years. The reason behind such a choice? David is working to defend the bacteria that live on his skin—as it does on ours—but Whitlock also believes it’s in our best interest to keep […]

Read more

How Bell Biosystems is using naturally magnetic bacteria to track cell therapies

With FDA calling for non-invasive new tracking systems to accompany cell therapies, Bell Biosystems Inc. wants its Magnelle trackers to become the technology of choice. While the magnetic organelles’ longevity and strong signals lend the agents advantages for large animal and human studies, the company is hoping to make its mark in the preclinical space before tackling what will likely […]

Read more

Amarantus Announces Issuance of Australian Patent

Amarantus Announces Issuance of Australian Patent Covering Eltoprazine Treatment of Parkinson’s Disease and Alzheimer’s Disease Amarantus Bioscience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapeutic and diagnostic product candidates in orphan indications and neurology, today announced the issuance of Australian patent no. 61/057,713 covering the use of Eltoprazine for the treatment of various neurological and mental disorders, including Parkinson’s disease, […]

Read more

Blueprint Genetics Plans to Boost Inherited Disease Panel Portfolio Next Year

Finnish hereditary disease diagnostics firm Blueprint Genetics plans to significantly expand its portfolio of clinical gene panel tests next year, and in the meantime has been pushing into new territories, including the US. The Helsinki-based firm started offering diagnostic gene panels for inherited cardiovascular disorders two years ago, using a targeted sequencing technology called OS-Seq that one of its co-founders […]

Read more

Symic Biomedical Selects Osteoarthritis Clinical Candidate

Symic Biomedical, a clinical-stage biotherapeutics company developing multiple compounds that target and affect the extracellular matrix (ECM), today announced the selection of SB-061 as the company’s first osteoarthritis clinical candidate. In preclinical studies, SB-061 was shown to reduce pain and cartilage degradation in models of osteoarthritis. SB-061, which will be administered as an intra-articular injection, is designed to prevent the […]

Read more

A guy who hasn’t showered in 12 years just helped launch a skin care company

Forgoing a shower, even for a day, makes some people want to hide from society and double up on the deodorant. For Dave Whitlock, this is simply life as usual. The chemical engineer and MIT grad decided back in 2003 to stop showering after discovering that animals harness bacteria in mud to stay odor-free. Called Nitrosomonas, these bacteria break down […]

Read more

A new dawn for cataracts

On Thursday, November 6, scientists from ViewPoint Therapeutics published an article titled “Pharmacological chaperone for α-crystallin partially restores transparency in cataract models” in Science Magazine. The lead author: ViewPoint’s founder and CSO, Leah Makley. The summary below is from the linked perspective in the same issue. Cataract, a clouding of the eye lens, is the major cause of blindness in […]

Read more

Symic Biomedical Advances First Product Candidate, SB-030, Into Clinical Development

Symic Biomedical, a clinical-stage biotherapeutics platform company developing compounds that target the extracellular matrix (ECM), today announced the treatment of the first patient in its Phase 1/2 clinical Study in Humans to Investigate the Efficacy and Safety of Luminal SB-030 Delivery in Peripheral Artery Disease (SHIELD Trial). The study will evaluate the safety and efficacy of SB-030 (previously SBCV-030), a […]

Read more

Amarantus seeks US FDA orphan drug status for eltoprazine

Amarantus Bioscience Holdings, Inc., a biotechnology company, has submitted a request to the US FDA for orphan drug designation (ODD) for eltoprazine in the treatment of levodopa-induced dyskinesia (PD-LID). “A successful application to the US FDA for ODD for eltoprazine in PD LID would complete the transition of our therapeutics portfolio into the orphan drug arena, thereby squarely positioning Amarantus […]

Read more

Military researchers to conduct trial of Amarantus’s “engineered skin substitute”

Cooperative research and development efforts with the military, universities and the biotech industry can potentially lead to advancements in the treatment of severe wounds.  Biotech companies with recent developments, partnerships and advancements in focus are Amarantus Bioscience Holdings, Inc. (OTCQX: AMBS), Array BioPharma, Inc. (NASDAQ: ARRY), Avanex Life Sciences Corp. (OTCQX: AVXLD), Juno Therapeutics, Inc. (NASDAQ: JUNO), and Progenix Pharmaceuticals, […]

Read more
Page 5 of 8« First...34567...Last »

Upcoming Event

  • Reaction before action: new approaches to biomineralization-associated diseases

    Daniel Laser, PhD CEO and Co-Founder, Applaud Medical RSVP Applaud Medical is a three-year-old company developing treatments for biomineralization-related diseases. Applaud's products use violent physical effects like cavitation and shock waves to achieve a therapeutic effect, while sparing non-targeted tissue through precise chemical targeting. Applaud's lead product, for low-invasiveness treatment of kidney stones, is currently in clinical trials in Gujarat, India. This seminar will cover technical aspects of combining chemical reactions with mechanical action in both Applaud's products and in a range of other drugs and devices, along with a brief discussion of key commercialization considerations for this uniquely promising product category. About Daniel Laser Daniel Laser is Chief Executive Officer and co-founder of Applaud Medical. Dan also founded Wave 80 Biosciences, a pioneer in detecting HIV during the high-transmission-risk earliest phase of infection, when the immune response is insufficiently advanced for antibody-based methods. He has served as board member or advisor to drug and device companies in fields ranging from autoimmune disease to ophthalmology to cancer. Dan got his start in the medical device field working on haptic feedback for telerobotic surgery systems. Dan holds a Ph.D. in mechanical engineering from Stanford University, where he was a Semiconductor Research Corporation Graduate Fellow. While at Stanford, he was also a MacArthur Affiliate at Stanford’s Center for International Security and Cooperation, developing mathematical models for protecting against threats involving weaponized pathogens.


953 Indiana St., San Francisco, CA 94107
Tel: (415)-347-8287

Sign-Up for our Newsletter